https://www.nasdaq.com/press-release/bluebird-bio-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2022-01
https://www.nasdaq.com/press-release/bluebird-bio-announces-partial-clinical-hold-for-patients-under-18-in-sickle-cell
https://www.nasdaq.com/press-release/bluebird-bio-announces-fda-priority-review-of-biologics-license-application-for-eli
https://www.nasdaq.com/press-release/new-and-updated-data-demonstrating-sustained-treatment-response-in-patients-treated
https://www.nasdaq.com/press-release/new-data-at-ash21-published-in-nejm-further-demonstrate-beti-cel-as-a-potentially
https://www.nasdaq.com/press-release/bluebird-bio-announces-fda-priority-review-of-biologics-license-application-for-beti
https://www.nasdaq.com/press-release/bluebird-bio-reports-third-quarter-financial-results-and-recent-operational-progress
https://www.nasdaq.com/press-release/bluebird-bio-and-federal-realty-to-establish-biotech-footprint-at-assembly-row-2021
https://www.nasdaq.com/press-release/bluebird-bio-to-present-new-gene-therapy-data-at-the-63rd-american-society-of
https://www.nasdaq.com/press-release/bluebird-bio-completes-planned-business-separation-2021-11-04
https://www.nasdaq.com/press-release/bluebird-bio-sets-record-date-and-distribution-date-for-planned-business-separation
https://www.nasdaq.com/press-release/bluebird-bio-provides-update-on-upcoming-planned-business-separation-2021-10-08
https://www.nasdaq.com/press-release/bluebird-bio-submits-biologics-license-application-bla-to-fda-for-betibeglogene
https://www.nasdaq.com/press-release/2seventy-bio-announces-upcoming-investor-events-2021-09-13
https://www.nasdaq.com/press-release/bluebird-bio-secures-%2475-million-in-private-placement-equity-financing-2021-09-08
https://www.nasdaq.com/press-release/bluebird-bio-announces-key-management-and-board-appointments-and-upcoming-investor
https://www.nasdaq.com/press-release/bluebird-bio-reports-second-quarter-financial-results-and-provides-operational-update
https://www.nasdaq.com/press-release/bluebird-bio-announces-q2-earnings-call-and-upcoming-investor-events-2021-08-05
https://www.nasdaq.com/press-release/bluebird-bio-inc.-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-08
https://www.nasdaq.com/press-release/bluebird-bio-and-resilience-announce-strategic-alliance-to-develop-next-generation
https://www.nasdaq.com/press-release/bluebird-bio-receives-ec-approval-for-skysonatm-elivaldogene-autotemcel-lenti-dtm
https://www.nasdaq.com/press-release/bluebird-bio-announces-positive-recommendation-by-prac-regarding-article-20-safety
https://www.nasdaq.com/press-release/betibeglogene-autotemcel-beti-cel-one-time-gene-therapy-for-b-thalassemia-continues
https://www.nasdaq.com/press-release/bluebird-bio-to-present-at-goldman-sachs-global-healthcare-conference-2021-06-07
https://www.nasdaq.com/press-release/bluebird-bio-announces-the-lifting-of-fda-clinical-hold-for-sickle-cell-disease-and-b
https://www.nasdaq.com/press-release/bluebird-bio-inc.-reports-inducement-grants-to-cco-tom-klima-under-nasdaq-listing
https://www.nasdaq.com/press-release/bluebird-bio-receives-positive-chmp-opinion-for-skysonatm-elivaldogene-autotemcel
https://www.nasdaq.com/press-release/long-term-data-from-pivotal-karmma-study-continue-to-demonstrate-deep-and-durable
https://www.nasdaq.com/press-release/aavantibio-rounds-out-leadership-team-with-appointment-of-jessie-hanrahan-ph.d.-as
https://www.nasdaq.com/press-release/bluebird-bio-to-present-data-from-its-severe-genetic-disease-and-oncology-portfolios
https://www.nasdaq.com/press-release/bluebird-bio-reports-first-quarter-financial-results-and-highlights-operational
https://www.nasdaq.com/press-release/bluebird-bio-announces-may-investor-events-2021-05-03
https://www.nasdaq.com/press-release/bluebird-bio-provides-update-on-severe-genetic-disease-programs-and-business
https://www.nasdaq.com/press-release/u.s.-food-and-drug-administration-approves-bristol-myers-squibbs-and-bluebird-bios
https://www.nasdaq.com/press-release/bluebird-bio-presents-long-term-data-for-elivaldogene-autotemcel-eli-cel-lenti-dtm
https://www.nasdaq.com/press-release/bluebird-bio-provides-updated-findings-from-reported-case-of-acute-myeloid-leukemia
https://www.nasdaq.com/press-release/bluebird-bio-to-present-at-cowen-health-care-conference-2021-02-26
https://www.nasdaq.com/press-release/the-new-england-journal-of-medicine-publishes-results-from-pivotal-phase-2-karmma
https://www.nasdaq.com/press-release/bluebird-bio-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/bluebird-bio-to-present-at-leerink-global-healthcare-conference-2021-02-22
https://www.nasdaq.com/press-release/bluebird-bio-inc.-class-action-alert%3a-wolf-haldenstein-adler-freeman-herz-llp
https://www.nasdaq.com/press-release/blue-stock%3a-berger-montague-investigates-alleged-securities-fraud-claims-against
https://www.nasdaq.com/press-release/blue-shareholder-filing-deadline%3a-bernstein-liebhard-llp-reminds-investors-of-the
https://www.nasdaq.com/press-release/blue-investor-alert%3a-bronstein-gewirtz-grossman-llc-notifies-bluebird-bio-inc.
https://www.nasdaq.com/press-release/bluebird-bio-announces-temporary-suspension-on-phase-1-2-and-phase-3-studies-of
https://www.nasdaq.com/press-release/bluebird-bio-to-separate-oncology-business-into-independent-company-2021-01-11
https://www.nasdaq.com/press-release/shape-therapeutics-announces-appointment-of-gary-fortin-as-chief-operating-officer
https://www.nasdaq.com/press-release/treatment-with-investigational-lentiglobintm-gene-therapy-for-sickle-cell-disease
https://www.nasdaq.com/press-release/long-term-data-for-bluebird-bios-betibeglogene-autotemcel-beti-cel-gene-therapy-show
https://www.nasdaq.com/press-release/bristol-myers-squibb-and-bluebird-bio-present-data-highlighting-anti-bcma-car-t-cell
https://www.nasdaq.com/press-release/magenta-therapeutics-and-bluebird-bio-announce-a-phase-2-clinical-trial-collaboration
https://www.nasdaq.com/press-release/bluebird-bio-announces-live-webcast-to-review-clinical-data-presented-at-the-0
https://www.nasdaq.com/press-release/bluebird-bio-announces-november-investor-events-2020-11-10
https://www.nasdaq.com/press-release/bluebird-bio-to-present-data-from-gene-and-cell-therapy-programs-during-the-62nd
https://www.nasdaq.com/press-release/bluebird-bio-reports-third-quarter-2020-financial-results-and-highlights-operational
https://www.nasdaq.com/press-release/bluebird-bio-announces-european-medicines-agencys-acceptance-of-marketing
https://www.nasdaq.com/press-release/bluebird-bio-to-present-at-jefferies-cell-therapy-virtual-summit-2020-09-28
https://www.nasdaq.com/press-release/bluebird-bios-lentiglobintm-for-sickle-cell-disease-gene-therapy-bb1111-granted
https://www.nasdaq.com/press-release/u.s.-food-and-drug-administration-fda-accepts-for-priority-review-bristol-myers-1
https://www.nasdaq.com/press-release/bluebird-bio-announces-september-investor-events-2020-09-02
https://www.nasdaq.com/press-release/bluebird-bio-presents-new-results-from-clinical-development-program-of-elivaldogene
https://www.nasdaq.com/press-release/bluebird-bio-to-present-new-data-from-clinical-studies-of-elivaldogene-autotemcel-eli
https://www.nasdaq.com/press-release/bluebird-bio-appoints-denice-torres-to-board-of-directors-2020-08-11
https://www.nasdaq.com/press-release/bluebird-bio-reports-second-quarter-2020-financial-results-and-recent-operational
